Fulcrum Therapeutics, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Fulcrum Therapeutics, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($74.88M) | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | ($9.73M) | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | ($97.34M) | Feb 25, 2025 |
| FY2023 | Dec 31, 2022 | ($109.87M) | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | ($80.85M) | Jun 26, 2023 |
| FY2021 | Dec 31, 2020 | ($70.82M) | Jun 26, 2023 |
| FY2020 | Dec 31, 2019 | ($82.68M) | Jun 23, 2023 |
| FY2019 | Dec 31, 2018 | ($32.59M) | Mar 5, 2020 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($84.77M) | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | ($21.90M) | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | ($110.66M) | Feb 25, 2025 |
| FY2023 | Dec 31, 2022 | ($112.56M) | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | ($81.05M) | Jun 26, 2023 |
| FY2021 | Dec 31, 2020 | ($71.61M) | Jun 26, 2023 |
| FY2020 | Dec 31, 2019 | ($84.22M) | Jun 23, 2023 |
| FY2019 | Dec 31, 2018 | ($33.50M) | Mar 5, 2020 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $366.28M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $260.72M | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | $257.69M | Feb 25, 2025 |
| FY2023 | Dec 31, 2022 | $226.69M | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | $235.00M | Jun 26, 2023 |
| FY2021 | Dec 31, 2020 | $129.58M | Jun 26, 2023 |
| FY2020 | Dec 31, 2019 | $110.44M | Jun 23, 2023 |
| FY2019 | Dec 31, 2018 | $85.77M | Mar 5, 2020 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $17.28M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $17.68M | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | $22.50M | Feb 25, 2025 |
| FY2023 | Dec 31, 2022 | $27.74M | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | $23.46M | Jun 26, 2023 |
| FY2021 | Dec 31, 2020 | $34.40M | Jun 26, 2023 |
| FY2020 | Dec 31, 2019 | $23.29M | Jun 23, 2023 |
| FY2019 | Dec 31, 2018 | $9.77M | Mar 5, 2020 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $349.00M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $243.03M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $235.19M | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $198.94M | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | $211.54M | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | $95.18M | Jun 26, 2023 |
| FY2021 | Dec 31, 2019 | $87.15M | Jun 26, 2023 |
| FY2020 | Dec 31, 2018 | ($63.67M) | Jun 23, 2023 |
| FY2019 | Dec 31, 2017 | ($33.27M) | Mar 5, 2020 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | (1) | Feb 25, 2025 |
| FY2023 | Dec 31, 2022 | (2) | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | (2) | Jun 26, 2023 |
| FY2021 | Dec 31, 2020 | (2) | Jun 26, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | (1) | Feb 25, 2025 |
| FY2023 | Dec 31, 2022 | (2) | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | (2) | Jun 26, 2023 |
| FY2021 | Dec 31, 2020 | (2) | Jun 26, 2023 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $197.53M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $58.21M | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | $25.56M | Feb 25, 2025 |
| FY2023 | Dec 31, 2022 | $35.10M | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | $35.41M | Jun 26, 2023 |
| FY2021 | Dec 31, 2020 | $57.05M | Jun 26, 2023 |
| FY2020 | Dec 31, 2019 | $96.71M | Jun 23, 2023 |
| FY2019 | Dec 31, 2018 | $72.80M | Mar 5, 2020 |